News & Videos - ICO THERAPEUTICS ICOTF - Page 2

Vancouver, British Columbia--(Newsfile Corp. - October 21, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that two poster presentations regarding iCo's Oral Amphotericin B technology (iCo-019) will be highlighted at the AAPS 2020 PharmSci 360 Virtual Meeting October 26 - November 5, 2020. AAPS is the preeminent global scientific organization of more than 10,000 actively participating...

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended June 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). Stated William Jarosz, CEO of iCo Therapeutics Inc., "Our Q2 results show a marked quarter over quarter decline in our operating expenses compared to...

Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today the publication of results of their Oral Amphotericin B (iCo 019) Phase 1a Study in one of the leading infectious diseases journals, Antimicrobial Agents and Chemotherapy entitled "Phase I Clinical Study to evaluate the safety, tolerability, and pharmacokinetics of a novel oral...

Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended March 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). Stated William Jarosz, CEO of iCo Therapeutics Inc., "We were pleased with the positive outcome from our Phase 1b study of our oral amphotericin B...

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that the American Association of Pharmaceutical Scientists ("AAPS") has accepted two presentations regarding iCo's Oral Amphotericin B technology (iCo-019) for the AAPS 2020 PharmSci 360 Meeting to be held October 26-November 5, 2020 (the "PharmSci 360 Meeting"). AAPS is the preeminent...

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is providing an update on the status of the filing of its interim financial statements and accompanying management's discussion and analysis, and related CEO and CFO certifications for the three month period ended March 31, 2020 (collectively, the "Q1 Filings"). On March 18, 2020, the Canadian Securities Administrators announced that they will provide all...

Vancouver, British Columbia--(Newsfile Corp. - May 19, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the year ended December 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). Stated William Jarosz, President and CEO of iCo Therapeutics Inc., "2019 represented a year of significant advances as we entered into a Phase 1b...

Vancouver, British Columbia--(Newsfile Corp. - April 27, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is providing an update on the status of the filing of its annual financial statements and accompanying management's discussion and analysis, and related CEO and CFO certifications for the financial year ended December 31, 2019 (collectively, the "Annual Filings"). On March 18, 2020, the Canadian Securities Administrators announced that they will provide all...

Vancouver, British Columbia--(Newsfile Corp. - April 15, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") announced today the successful results of a Phase 1b clinical study of iCo's Oral Amphotericen B Delivery System ("Amp B" or "iCo 019") which began on December 9, 2019. The purpose of the study was to evaluate the safety, tolerability and pharmacokinetics of 100mg and 400mg doses of iCo 019. iCo also announced the appointment of Dr. Kishor Wasan as Director...

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") announces that Andrew Rae, MBA, has resigned from his roles as both President & CEO and Director. Mr. Rae has agreed to assist management, through to the end of the fiscal quarter, to ensure a smooth and orderly transition. iCo also announces today that Susan Koppy will immediately assume the role of President and William Jarosz will immediately assume the...

Vancouver, British Columbia--(Newsfile Corp. - February 25, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today a positive primary endpoint with respect to its Phase 1b Oral Amphotericin B (Oral Amp B) study. In the Phase 1b study all repeat doses were well-tolerated, with no serious adverse events. There were no signs of kidney or other toxicities. Dr. Peter Hnik, Chief Medical Officer of iCo,...

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in its Phase 1b study have received doses of Oral Amphotericin B (either 100mg and 400mg/day) over ten days and, subsequent to dosing, have been followed up for an additional ten days. Full results of the Phase 1b study are currently expected before the end of Q1...

Vancouver, British Columbia--(Newsfile Corp. - January 10, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today granted 2,000,000 stock options to directors, officers and an advisor. The stock options are exercisable at the price of $0.08 and will expire on January 10, 2025. The stock options shall vest as follows: 1/5 on today's date (the "Effective Date") and then 1/5 every six months until all options are vested. The closing price of the Company's shares on the...

Vancouver, British Columbia--(Newsfile Corp. - December 24, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in the first of two cohorts in its Phase 1b study have received 100 mg doses of Oral Amphotericin B on a daily basis over ten days, with no drug-related adverse events observed to date. One additional cohort is expected to be dosed in early Q1 2020, followed by the...

Vancouver, British Columbia--(Newsfile Corp. - December 11, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") today announced it has engaged Ora, Inc., the world's leading full-service ophthalmic CRO and product development firm, to assist the Company with its ophthalmic regulatory and development strategy for iCo-008. It is expected that this work will ultimately result in a meeting with the FDA prior to initiation of a Phase 2 trial. Ora has vast expertise in...

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in the first of two cohorts in its Phase 1b study have received the first dose of Oral Amphotericin B. Dosing will occur over a period of ten days. One additional cohort is expected to be dosed in Q1 2020, followed by the initiation of a Phase II study comparing oral...

Vancouver, British Columbia--(Newsfile Corp. - December 2, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the Quarter ended September 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "Several important milestones have been achieved in recent weeks with ethics...

Vancouver, British Columbia--(Newsfile Corp. - November 25, 2019) - iCo Therapeutics Inc. ( TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced today that the purchase of the assets of Immune Pharmaceuticals ("Immune"), including the sublicense of iCo-008, by Alexion Pharmaceuticals, Inc. ("Alexion") has received all requisite court approvals and the closing of the purchase transaction is expected prior to the end of Q1 2020. Alexion has assumed Immune's rights and obligations under the...

Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its Australian subsidiary, iCo Therapeutics Pty Ltd., today announced several developments related to its wholly-owned oral Amphotericin B (Oral Amp B) asset and current marketing and partnering efforts. Oral Amphotericin B ("Oral Amp B") Clinical Program: Currently iCo and its partner contract research organizations ("CROs") expect dosing of the first...

Vancouver, British Columbia--(Newsfile Corp. - October 22, 2019) - iCo Therapeutics Inc. ("iCo" or "the Company") (TSXV: ICO) (OTCQB: ICOTF) today announced several corporate developments. iCo has been monitoring a current US court-mandated auction process, with respect to systemic uses of Bertilimumab, previously sublicensed to Immune Pharmaceuticals. On October 21, 2019, the bankruptcy court in New Jersey approved a sale order relating to the assignment of the sublicense of iCo's assets to...